Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate is MIE-101 which is based on cowpea mosaic virus which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.